Interessante Fakten

• Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results - MarketWatch (press release)
  

  Jazz Pharmaceuticals Announces First Quarter 2012 Financial ResultsMarketWatch (press release)Psychiatry Products: Net sales of the company's psychiatry products, including once-daily Luvox CR® (fluvoxamine maleate), FazaClo HD and FazaClo LD were $17.

• Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results - PR Newswire (press release)
  

  Jazz Pharmaceuticals Announces First Quarter 2012 Financial ResultsPR Newswire (press release)Psychiatry Products: Net sales of the company's psychiatry products, including once-daily Luvox CR® (fluvoxamine maleate), FazaClo HD and FazaClo LD were $17.

• Jazz Pharma jumps on $700M deal for EUSA Pharma - BusinessWeek
  

  Jazz Pharma jumps on $700M deal for EUSA PharmaBusinessWeekSales totaled $33 million in the first quarter, including $25 million in the US Jazz makes the narcolepsy drug Xyrem, which brings in most of its revenue, and the obsessive compulsive disorder treatment Luvox CR.

• Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference ... - MarketWatch (press release)
  

  Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference .

• Jazzed up for M&A, VCs Get a Return - Private Equity Hub (press release)
  

  Jazzed up for M&A, VCs Get a ReturnPrivate Equity Hub (press release)The company's marketed products in these areas include: Xyrem® (sodium oxybate), Prialt® (ziconotide intrathecal infusion), FazaClo® (clozapine USP) HD and LD, Luvox CR® (fluvoxamine maleate) and Elestrin® (estradiol gel 0.